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Abstract: BACKGROUND Controversial results on maternal risk and fetal outcome have been reported
in women with aortic stenosis (AS). OBJECTIVES The authors sought to investigate maternal and fetal
outcomes in patients with AS in a large cohort. METHODS The Registry on Pregnancy and Cardiac
Disease (ROPAC) is a global, prospective observational registry of women with structural heart disease,
providing a uniquely large study population. Data of women with moderate (peak gradient 36 to 63
mm Hg) and severe AS (peak gradient ฀64 mm Hg) were analyzed. RESULTS Of 2,966 pregnancies
in ROPAC, the authors identified 96 women who had at least moderate AS (34 with severe AS). No
deaths were observed during pregnancy and in the first week after delivery. However, 20.8% of women
were hospitalized for cardiac reasons during pregnancy. This was significantly more common in severe AS
compared with moderate AS (35.3% vs. 12.9%; p = 0.02), and reached the highest rate (42.1%) in severe,
symptomatic AS. Pregnancy was complicated by heart failure in 6.7% of asymptomatic and 26.3% of
symptomatic patients, but could be managed medically, except for 1 patient who was symptomatic before
pregnancy and underwent balloon valvotomy. Children of patients with severe AS had a significantly
higher percentage of low birth weight (35.0% vs. 6.0%; p = 0.006). CONCLUSIONS Mortality in
pregnant women with AS, including those with severe AS, appears to be close to zero in the current era.
Symptomatic and severe AS does, however, carry a substantial risk of heart failure and is associated with
high rates of hospitalization for cardiac reasons, although heart failure can nearly always be managed
medically. The results highlight the importance of appropriate pre-conceptional patient evaluation and
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DOI: https://doi.org/10.1016/j.jacc.2016.07.750






The following work is licensed under a Creative Commons: Attribution 4.0 International (CC BY 4.0)
License.
Originally published at:
Orwat, Stefan; Diller, Gerhard-Paul; van Hagen, Iris M; Schmidt, Renate; Tobler, Daniel; Greutmann,
Matthias; Jonkaitiene, Regina; Elnagar, Amro; Johnson, Mark R; Hall, Roger; Roos-Hesselink, Jolien
W; Baumgartner, Helmut (2016). Risk of Pregnancy in Moderate and Severe Aortic Stenosis: From the
Multinational ROPAC Registry. Journal of the American College of Cardiology, 68(16):1727-1737.
DOI: https://doi.org/10.1016/j.jacc.2016.07.750
2
Risk of Pregnancy in Moderate and
Severe Aortic Stenosis
From the Multinational ROPAC Registry
Stefan Orwat, MD,a Gerhard-Paul Diller, MD, PHD, MSC,a Iris M. van Hagen, MD,b Renate Schmidt, MD,a
Daniel Tobler, MD,c Matthias Greutmann, MD,d Regina Jonkaitiene, MD,e Amro Elnagar, MD,f
Mark R. Johnson, MD, PHD,g Roger Hall, MD,h Jolien W. Roos-Hesselink, MD, PHD,b,i Helmut Baumgartner, MD,a
on behalf of the ROPAC Investigators
ABSTRACT
BACKGROUND Controversial results on maternal risk and fetal outcome have been reported in women with aortic
stenosis (AS).
OBJECTIVES The authors sought to investigate maternal and fetal outcomes in patients with AS in a large cohort.
METHODS The Registry on Pregnancy and Cardiac Disease (ROPAC) is a global, prospective observational registry of
women with structural heart disease, providing a uniquely large study population. Data of women with moderate
(peak gradient 36 to 63 mm Hg) and severe AS (peak gradient $64 mm Hg) were analyzed.
RESULTS Of 2,966 pregnancies in ROPAC, the authors identified 96 women who had at least moderate AS (34 with
severe AS). No deaths were observed during pregnancy and in the first week after delivery. However, 20.8% of women
were hospitalized for cardiac reasons during pregnancy. This was significantly more common in severe AS compared with
moderate AS (35.3% vs. 12.9%; p ¼ 0.02), and reached the highest rate (42.1%) in severe, symptomatic AS. Pregnancy
was complicated by heart failure in 6.7% of asymptomatic and 26.3% of symptomatic patients, but could be managed
medically, except for 1 patient who was symptomatic before pregnancy and underwent balloon valvotomy. Children
of patients with severe AS had a significantly higher percentage of low birth weight (35.0% vs. 6.0%; p ¼ 0.006).
CONCLUSIONS Mortality in pregnant women with AS, including those with severe AS, appears to be close to zero in
the current era. Symptomatic and severe AS does, however, carry a substantial risk of heart failure and is associated with
high rates of hospitalization for cardiac reasons, although heart failure can nearly always be managed medically.
The results highlight the importance of appropriate pre-conceptional patient evaluation and counseling.
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P
regnancy carries a very low risk of
death in developed countries, but
overall, cardiac reasons remain the
leading cause of maternal mortality (1).
Consistent with this, women with pre-
existing heart disease have 100 times greater
mortality than normal (2). Pregnancy is asso-
ciated with profound changes in hemody-
namic parameters, perhaps explaining why
pre-existing heart disease has such an
adverse impact on morbidity and mortality
in pregnant women (3). Although there is
clear evidence that pregnancy is a high-risk
endeavor in women with complex heart dis-
ease, and especially those with severe pulmonary hy-
pertension (4,5), available data are limited in women
with less complex heart disease. Obstructive heart le-
sions will be aggravated by the increase in stroke vol-
ume occurring with pregnancy, and are therefore of
particular concern. Aortic stenosis (AS) is one of these
lesions, but it is relatively uncommon in women of
childbearing age. However, when present, it has
been reported to be associated with an increased
risk of maternal cardiovascular events, including
death, obstetric morbidity (such as pre-term birth),
and fetal complications, including growth restriction,
miscarriage, and stillbirth (6). The evidence in this
setting is nevertheless limited, and the results of pub-
lished reports are conflicting. Unfortunately, prior
studies either encompassed all forms of heart disease
(7,8) or included mild AS (9). In addition, some series
report on historic patient cohorts (6). As a conse-
quence, the reported maternal mortality rate ranges
between 2% and 17.4%, and the risk in contemporary
cohorts of women presenting with severe AS remains
unclear (6,9).
The purpose of this study was therefore to investi-
gate maternal and fetal adverse events in contempo-
rary patients with moderate or severe AS on the basis
of a prospective observational study of a large number
of pregnancies in patients with AS included in ROPAC
(Registry of Pregnancy and Cardiac Disease).
METHODS
ROPAC is a global, prospective, observational registry
of women with heart disease. It was initiated by the
European Society of Cardiology (ESC) working groups
on congenital heart disease and valvular heart dis-
ease, and is part of the EURObservational Research
Programme of the ESC. The registry allows for the
inclusion of patients with structural or ischemic
heart disease, aortic pathology, and pulmonary hy-
pertension. The registry started in January 2008. Pa-
tients who were pregnant in 2007 could also be
included retrospectively; from January 2008, patients
were included prospectively. Patients were managed
at the discretion of the attending physicians. The
overall mortality during pregnancy and until 1 week
after delivery in the registry has been reported at 1%.
Further details on the registry and the institutional
review board/ethical approval have previously been
published (2,10). The current study is covered by
approval under the umbrella of the general ROPAC
project.
The present study retrospectively analyzed the
outcome and complications in pregnant women with
moderate or severe AS included in the registry up to
April 2014. We focused exclusively on women with
moderate or severe AS. Patients with additional con-
genital or acquired heart disease (with the exception of
simple corrected pre-tricuspid shunts, aortic coarcta-
tion) were not included in the current study. The
severity of AS was graded on the basis of available
transthoracic echocardiographic data at baseline.
Moderate ASwas defined as a peak transaortic gradient
$36 mm Hg (corresponding to a peak velocity $3 m/s),
whereas severe AS was defined as a peak aortic
gradient $64 mm Hg (corresponding to a peak
velocity $4 m/s) using the simplified Bernoulli equa-
tion (11,12). This is in agreement with current guide-
lines and general recommendations for assessing the
severity of AS in the presence of normal flow rate (13).
Patients who had undergone aortic valve replacement
before pregnancy were included if they fulfilled the
hemodynamic criteria described in the preceding text.
However, further analyses were also performed and
presented separately because prosthetic valve-related
risks require additional consideration. Repeated
pregnancies were excluded from the analysis.
Baseline characteristics included maternal age,
general cardiovascular risk factors, major noncardiac
disease, cardiac diagnosis, prior interventions, car-
diac symptoms, medication, and obstetric history.
Heart failure before pregnancy was defined according
to current guidelines clinically as a syndrome in
which patients have typical symptoms (e.g., breath-
lessness, ankle swelling, and fatigue) and signs
(e.g., elevated jugular venous pressure, pulmonary
crackles, and displaced apex beat) (14). Maternal
mortality was defined as death during pregnancy or
up to 1 week after delivery. Miscarriage was defined
as loss of pregnancy up to 24 weeks of gestation or a
fetus weighting <500 g, whereas fetal mortality was
defined as fetal loss beyond 24 weeks of pregnancy.
Outcome measures included maternal mortality,
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maternal hospital admission (all-cause and admission
for cardiac reasons), pre-term labor (<37 weeks of
gestation), neonatal mortality (neonatal death <30
days postpartum), low birth weight (defined as a birth
weight <2,500 g according to World Health Organi-
zation [WHO] criteria), small for gestational age ne-
onates (weight below the 10th percentile for
gestational age), and the need for Cesarean section.
STATISTICAL ANALYSIS. Data are presented as
numbers (percentage) for categorical variables or
mean  SD or median (interquartile range [IQR]: 25th
to 75th percentile) for continuous variables, depend-
ing on data distribution. Groups were compared
with the use of chi-square tests, Student t tests, or
nonparametric Mann-Whitney U tests, respectively.
The relation between baseline parameters and
outcome was assessed with the use of univariable and
multivariable logistic regression analyses, and odds
ratios (ORs) with 95% confidence intervals are pro-
vided. Models were built by including significant
univariable parameters into a multivariable analysis.
For all analyses, a 2-tailed p value <0.05 was used as
the criterion for statistical significance. Analyses were
performed with the use of Medcalc statistical software
version 14.12.0 (Medcalc Software, Ostend, Belgium).
RESULTS
BASELINE CHARACTERISTICS. Using the ROPAC
registry, which included 2,966 pregnancies from 99
centers in 40 countries (enrolled between 2008 and
2014), we identified women with at least moderate
AS, who had adequate baseline echocardiographic
data. After exclusion of 3 patients with associated
significant congenital heart disease (1 with ventricu-
lar septal defect, 1 with Tetralogy of Fallot, and 1 with
a double outlet right ventricle), 96 women remained
and were included in the study. Echocardiographic
baseline investigations were performed at a mean
of 52  347 days before conception in these patients.
Of these, 44% were performed before conception. No
significant difference in the mean peak aortic
gradient was seen between patients with and without
pre-conceptional echocardiographic assessment (59 
22 mm Hg vs. 64  29 mm Hg; p ¼ 0.33). Overall, 22
women already had 1 child, 17 women had 2 children,
and 13 had 3 or more children. Baseline maternal
characteristics are presented in Table 1. The median
age at pregnancy was 30 years. Before pregnancy,
62.5% of AS patients were asymptomatic, whereas
33.3% were classified as New York Heart Association
(NYHA) functional class II and 4.2% as NYHA func-
tional class III. Approximately 50% of patients had a
previous successful pregnancy. Stratifying patients
by the severity of the underlying AS revealed that the
34 women with severe AS were more likely to be
symptomatic or to have pre-existing heart failure
symptoms (Table 1). In the current study, bicuspid
aortic valve was the most prevalent etiology for AS
(53.5%). In addition, 18 patients had rheumatic aortic
valve disease. None of the patients had connective
tissue disorders, such as Marfan or Ehlers-Danlos
syndrome. Two patients had aortic dilation (45 mm
and 50 mm aortic diameter). In total, 12 patients had
repaired aortic coarctation (9 with bicuspid aortic
valve). The mean peak aortic gradient was 62.1  26.3
mm Hg, whereas the mean aortic gradient was 39.1 
17.9 mm Hg. With the exception of 1 woman with an
ejection fraction of 39%, all patients had normal left
ventricular systolic function.
Overall, 8 patients had a previously implanted
bioprosthesis (7 in the aortic position, 1 in the mitral
position). Of these, only the patient with the mitral
bioprosthesis had severe native AS (peak gradient
71 mm Hg, mean gradient 49 mm Hg), whereas the
patients with aortic bioprostheses exhibited only
moderate AS (peak gradient 47.1  6.5 mm Hg, mean
gradient 28.1 5.4mmHg). In addition, 13 patients had
a previously implanted mechanical heart valve (4 in
the mitral position, 10 in the aortic position, and 1 in
both positions). The peak and mean Doppler gradients
in those patients with a mechanical aortic valve were
64.4  26.7 mm Hg and 39.0  20.2 mm Hg, respec-
tively. Anticoagulation was performed with oral
vitamin K antagonists throughout pregnancy or staged
therapy with low molecular weight heparin during the
first trimester, followed by vitamin K antagonists in 10
patients. Low molecular weight heparin was used
throughout pregnancy in 3 patients. None of the pa-
tients in the entire cohort developed a valve throm-
bosis, including those with a mechanical aortic valve.
MATERNAL CARDIAC COMPLICATIONS. No patient
died during pregnancy or within 1 week postpartum.
However, cardiovascular events and hospitalizations
were common. Overall, 35.8% of patients had at least
1 hospital admission during pregnancy, with 20.8%
admitted for cardiac reasons (Table 2). Women with
severe AS were significantly more likely to be
admitted during pregnancy (35.3% cardiac admis-
sions) than those with only moderate AS (12.9%,
p ¼ 0.02). Heart failure, first hospital admission for
cardiac reasons, and hospital admissions for all rea-
sons occurred at a mean gestational time of 27.2  7.5
weeks, 24.3  9.7 weeks, and 26.9  9.5 weeks,
respectively. The highest rate of hospitalization for
cardiac reasons was seen in symptomatic severe AS
patients, with a rate of 42.1%. Pregnancy was
J A C C V O L . 6 8 , N O . 1 6 , 2 0 1 6 Orwat et al.
O C T O B E R 1 8 , 2 0 1 6 : 1 7 2 7 – 3 7 Aortic Stenosis and Pregnancy
1729
complicated by heart failure in 6.7% of patients
asymptomatic before pregnancy and in 26.3% of
symptomatic patients with severe AS.
The leading cardiac complications were new or
worsening heart failure during pregnancy and ar-
rhythmias. By contrast, cerebrovascular complica-
tions or pulmonary embolism were not recorded in
this cohort, and only 1 patient was reported to have
developed endocarditis during pregnancy.
Heart failure could be managed medically in all pa-
tients, except for 1 case undergoing aortic valvotomy.
This patient, with a history of 2 previous pregnancies,
was unaware of the severe AS, although she had suf-
fered from severe dyspnea after a previous delivery.
She presented with critical AS and heart failure at 20
weeks of gestation, and had impaired left ventricular
systolic function. Aortic valvuloplasty was performed,
resulting in a reduction in both peak and mean gradi-
ents from 156 and 71mmHg pre-intervention to 113 and
55 mm Hg post-intervention, respectively, and in
moderate aortic regurgitation. The further course
of the pregnancy and delivery was uneventful.
The patient delivered a 3,200-g baby vaginally at 38
weeks. However, 1 month after delivery, the patient
presented again with severe symptoms and under-
went aortic valve replacement (AVR).
One patient underwent AVR with a mechanical
prosthesis during pregnancy as a consequence of
aortic valve endocarditis at 4 months into preg-
nancy. The further course of the pregnancy was
uneventful in this patient, with a vaginal delivery at
38 weeks.
OBSTETRIC AND FETAL OUTCOMES. Median preg-
nancy duration was 38.6 (IQR: 37.2 to 39.8) weeks, and
was significantly shorter in patients with severe AS
(37.9 [IQR: 35.2 to 39.0] weeks vs. 39.0 [IQR: 38.0 to
40.0] weeks; p ¼ 0.001) (Table 2). Women with severe
AS also had a significantly higher rate of Cesarean
section compared with those with moderate AS (75.0%
vs. 48.3%; p ¼ 0.008). The main reason for Cesarean
section was a cardiac indication, recorded in 65.9% of
patients. A low Apgar score (below 7) was present in
9.0% of neonates (5.2% vs. 16.1% of patients with
TABLE 1 Maternal Baseline Characteristics





Number of patients 96 62 34 60 36
Age in yrs 30.3 (26.0–32.8) 29.8 (26.3–32.9) 30.6 (25.9–32.7) 0.96 30.5 (26.2–33.4) 29.9 (25.8–32.8) 0.67
Nulliparous 47 (49) 36 (58.1) 11 (32.4) 0.028 36 (60) 11 (30.6) 0.01
Prior cardiac intervention 48 (50) 34 (54.8) 14 (41.2) 0.11 30 (50.0) 18 (50) 0.83
NYHA functional class
I 60 (62.5) 45 (72.6) 15 (44.1) 0.02 60 (100) — —
II 32 (33.3) 15 (24.2) 17 (50.0) — 32 (88.9)
III 4 (4.2) 2 (3.2) 2 (5.9) — 4 (11.1)
IV 0 (0) 0 (0) 0 (0) — 0 (0)
AS location
Valvular 59 (61.5) 45 (72.6) 18 (52.9) 0.02 35 (58.3) 24 (66.7) 0.49
Subvalvular 22 (22.9) 11 (17.7) 11 (32.4) 16 (26.7) 6 (16.7)
Supravalvular 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Not specified 15 (15.6) 10 (16.1) 5 (14.7) 9 (15.0) 6 (16.7)
Bicuspid aortic valve 46 (53.5) 34 (60.7) 12 (40.0) 0.18 35 (64.8) 11 (34.4) 0.02
Peak aortic gradient, mm Hg 62.1  26.3 47.5  6.9 88.7  28.0 <0.0001 56.8  20.1 71.1  32.7 0.006
Mean aortic gradient, mm Hg 39.1  17.9 27.8  5.3 55.1  17.4 <0.0001 35.4  16.0 44.3  19.5 0.006
Left ventricular function 65.6  8.7 67.4  6.2 62.4  11.5 0.27 66.6  7.1 64.0  10.7 0.60
Hypertension 11 (11.5) 9 (14.5) 2 (5.9) 0.35 6 (10) 5 (13.9) 0.80
Smoker, current or previous 11 (12.8) 8 (14.0) 3 (10.3) 0.73 7 (12.5) 4 (13.3) 0.73
Diabetes 0 (0) 0 (0) 0 (0) — 0 (0) 0 (0) —
Pre-existing heart failure symptoms 13 (13.5) 3 (4.8) 10 (29.4) 0.002 0 (0) 13 (36.1) <0.0001
Cardiac medication 14 (35.9) 9 (34.6) 5 (38.4) 0.91 8 (33.3) 6 (40.0) 0.94
Beta-blocker 7 (12.5) 4 (11.1) 3 (15.0) 0.22 5 (13.9) 2 (10.0) 0.56
ACE inhibitor/ARB 3 (5.4) 2 (5.6) 1 (5.0) 0.60 1 (2.8) 2 (10.0) 0.60
Anticoagulation 11 (19.6) 9 (33.3) 2 (10.0) 0.68 8 (22.2) 3 (15.0) 0.53
Values are n, median (IQR), n (%), or mean  SD. p Values refer to differences between patients with moderate and severe AS or asymptomatic and symptomatic patients, respectively. p
Values in bold are statistically significant.
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin-receptor blocker; AS ¼ aortic stenosis; IQR ¼ interquartile range; NYHA ¼ New York Heart Association.
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moderate and severe AS, respectively; p ¼ 0.21).
Children of patients with severe AS had significantly
lower birth weight (3,200 g [IQR: 2,932 to 3,490 g] vs.
3,000 g [IQR: 2,145 to 3,227 g]; p ¼ 0.0025).
There were 2 miscarriages (both in moderate AS),
no fetal losses between 24 weeks and delivery, and 1
neonatal death (in severe AS). The neonatal death
occurred after a pregnancy duration of 30 weeks and 2
days. The child that died was delivered by Cesarean
section, and was small for gestational duration, with a
weight of 1,000 g. The exact reason for delivery was
not documented, but the child died due to respiratory
distress syndrome. This event occurred in a mother
with severe AS, who had a previous unsuccessful
pregnancy complicated by heart failure and
arrhythmias.
PREDICTORS OF MATERNAL OR FETAL COMPLICATIONS.
Figures 1 to 3 present predictors of adverse maternal
or fetal outcome. As illustrated in Figure 1, the OR of
hospitalization in women with severe AS was 2.77
compared with those with only moderate AS. In
addition, peak aortic gradient on transthoracic echo-
cardiography was significantly associated with a
higher risk of maternal hospitalization during preg-
nancy (OR: 1.245/10 mm Hg; p ¼ 0.024). On multi-
variable analysis, peak aortic gradient emerged as an
independent predictor of maternal outcome.
Regarding fetal outcome, severity of AS and peak
aortic gradient on echocardiography again proved to
be independent predictors of low birth weight
(Figure 2) and small for gestational age neonates,
respectively (Figure 3).
DIFFERENCES BETWEEN COUNTRIES OF THE EUROPEAN
UNION/UNITED STATES, AND NON-EUROPEAN UNION
COUNTRIES. Seventy-four pregnancies were reported
from inside the European Union or the United States
(Group A), and 25 from outside (Group B). Group B
included 16 cases from Egypt, 5 from the Russian
Federation, 2 from the Arab Emirates, and 1 each
from Turkey and Serbia/Montenegro. Comparing
the 2 cohorts revealed no significant differences
between the groups regarding the severity of AS
TABLE 2 Maternal and Fetal Outcomes





Maternal mortality 0 — — — — — —
Maternal hospital admission 34 (35.8) 17 (27.4) 17 (51.5) 0.027 21 (35.0) 13 (37.1) 0.42
Maternal cardiac hospital admission 20 (20.8) 8 (12.9) 12 (35.3) 0.02 9 (15.0) 11 (30.6) 0.12
Cardiac complications
Heart failure 11 (11.5) 5 (8.1) 6 (17.6) 0.29 5 (8.3) 6 (16.7) 0.36
Arrhythmias (SVT) 1 (1.0) 1 (1.6) 0 (0) 0.76 1 (1.7) 0 (0) 0.80
Arrhythmias (VT/VF) 1 (1.0) 0 (0) 1 (2.9) 0.76 0 (0) 1 (2.8) 0.79
Endocarditis 1 (1.0) 1 (1.6) 0 (0) 0.76 1 (1.7) 0 (0) 0.80
Valve thrombosis 0 (0) 0 (0) 0 (0) — 0 (0) 0 (0) —
Cerebrovascular complication 0 (0) 0 (0) 0 (0) — 0 (0) 0 (0) —
Pulmonary embolism 0 (0) 0 (0) 0 (0) — 0 (0) 0 (0) —
Deep venous thrombosis 0 (0) 0 (0) 0 (0) — 0 (0) 0 (0) —
Obstetric complications
Pregnancy-induced hypertension 3 (3.2) 2 (3.2) 1 (3.0) 0.57 2 (3.3) 1 (2.9) 0.63
(Pre-)eclampsia 3 (3.2) 3 (4.8) 0 (0) 0.50 3 (5.0) 0 (0) 0.46
Cesarean section 54 (57.4) 30 (48.3) 24 (75.0) 0.008 30 (50.0) 24 (70.6) 0.029
Hemorrhagic events 4 (4.2) 4 (6.5) 0 (0) 0.33 4 (66.7) 0 (0) 0.29
Fetal outcome
Apgar score <7 8 (9.0) 3 (5.2) 5 (16.1) 0.21 4 (7.0) 4 (12.5) 0.37
Pregnancy duration (weeks) 37.2  5.2 38.0  4.4 35.5  6.4 0.002 37.0  6.2 37.5  2.8 0.08
Pre-term birth <37 weeks 18 (20.9) 8 (16.0) 10 (35.7) 0.017 10 (18.2) 8 (25.8) 0.49
Mean birth weight, g 3,010  691 3,198  549 2,648  797 0.003 3,091  642 2,878  758 0.24
Low birth weight (<2,500 g) 16 (16.2) 4 (6.0) 12 (35.0) 0.006 6 (10.0) 10 (27.8) 0.037
Small for gestational age 8 (9.3) 2 (3.4) 6 (21.4) 0.022 3 (5.5) 5 (16.1) 0.21
Miscarriages 2 (2.1) 2 (3.2) 0 (0) 0.76 2 (3.3) 0 (0) 0.71
Fetal death 0 (0) 0 (0) 0 (0) — 0 (0) 0 (0) —
Neonatal death 1 (1.1) 0 (0) 1 (3.3) 0.05 0 (0) 1 (3.0) 0.38
Values are n (%) or mean  SD. p Values refer to differences between patients with moderate and severe AS or asymptomatic and symptomatic patients, respectively. p Values
in bold are statistically significant.
AS ¼ aortic stenosis; SVT ¼ supraventricular tachycardia; VF ¼ ventricular fibrillation; VT ¼ ventricular tachycardia.
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(severe AS 28.3% in group A vs. 52.0% in group B
countries; p ¼ 0.057), the peak aortic gradient
(group A 59.7  25.8 mm Hg vs. group B 68.4  25.9
mm Hg; p ¼ 0.16) or the mean aortic gradient (group A
37.4  18.1 mm Hg vs. group B 42.9  16.6 mm Hg; p ¼
0.11). Women from Group B countries were, however,
more frequently symptomatic at baseline (56.0% vs.
29.7%; p ¼ 0.034) and had more hospital admissions
during pregnancy (52.0% vs. 30.1%; p ¼ 0.049 overall,
and 48.0% vs. 12.2%; p ¼ 0.0005 for cardiac reasons)
compared with those from Group A countries. The
rate of fetal complications, such as small for gesta-
tional age (group A 9.4% vs. group B 9.1%; p ¼ 0.70)
and pre-term birth (group A 21.7% vs. group B 14.3%;
p ¼ 0.40) was similar between the cohorts.
DISCUSSION
The current registry-based study suggests that mor-
tality risk in pregnant women with AS, including
FIGURE 2 Predictors of Low Birth Weight
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Severe aortic stenosis
Peak aortic gradient (per 10 mm Hg)





0.957 [95% CI 0.863–1.062]
1.893 [95% CI 0.402–3.517]
0.886 [95% CI 0.304–2.586]
1.685 [95% CI 0.408–6.961]
3.654 [95% CI 1.200–11.12]
8.318 [95% CI 2.426–28.52]
1.310 [95% CI 1.063–1.615]
1.134 [95% CI 0.907–1.418]
0.935 [95% CI 0.187–4.686]
1.179 [95% CI 0.389–3.575]
1.046 [95% CI 0.265–4.135]




Forrest plots illustrating the results of the univariate logistic regression analysis for adverse fetal outcome (low birth weight, defined as birth
weight <2,500 g). Severe aortic stenosis, peak aortic gradient, and NYHA class >1 at baseline were predictive of worse fetal outcome. An
asterisk denotes significant results. Abbreviations as in Figure 1.
FIGURE 1 Predictors of Adverse Maternal Outcome
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1.056 [95% CI 0.973–1.146]
1.376 [95% CI 0.599–3.163]
4.370 [95% CI 1.211–15.78]
1.101 [95% CI 0.466–2.601]
2.774 [95% CI 1.159–6.639]
1.245 [95% CI 1.029–1.505]
1.139 [95% CI 0.963–1.385]
0.887 [95% CI 0.247–3.186]
0.854 [95% CI 0.354–2.063]
1.325 [95% CI 0.445–3.859]
1.143 [95% CI 0.493–2.653]
*
*
Forrest plots illustrating the results of the univariate logistic regression analysis for adverse maternal outcome, defined as hospital admission
during pregnancy. Severe aortic stenosis and the peak aortic gradient were significantly related to worse outcome. An asterisk denotes
significant results. CI ¼ confidence interval; NYHA ¼ New York Heart Association.
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those with severe AS, is close to zero. However,
pregnancies may be associated with a relatively high
burden of morbidity, such as hospital admissions for
cardiac reasons in up to one-third of patients with
severe AS. The leading maternal complication during
pregnancy was heart failure, which occurred primar-
ily in patients with severe AS who were already
symptomatic before pregnancy. By contrast, patients
who were asymptomatic before pregnancy, even with
hemodynamically severe AS, had a relatively low rate
of heart failure occurrence (6.7%). It is alarming,
however, that over 50% of patients with severe AS
had symptoms before pregnancy, and therefore an
indication for valve replacement, emphasizing the
need for improvement in cardiac evaluation and
appropriate pre-conceptional counseling of patients.
Fortunately, heart failure could be managed medi-
cally in all but 1 woman. The main predictor of
maternal complications, besides symptoms of AS
before pregnancy, was the hemodynamic severity of
AS. Severe fetal complications were rare, but pre-term
birth and a low birth weight were observed in
approximately one-third of patients.
It is well recognized that valvular heart disease
patients are more likely than other groups of women
with structural heart disease to require hospitaliza-
tion, suffer from supraventricular arrhythmias, or
experience postpartum hemorrhagic complications. A
previous report using the ROPAC registry found aortic
valve disease to be present in 23% of pregnant pa-
tients with valvular heart disease, with AS being the
second most common stenotic valve lesion in this
cohort (2). Current guidelines consider symptomatic
severe AS to be a high-risk condition, and recommend
avoiding pregnancy (1,4). In asymptomatic patients, a
comprehensive preconception assessment, including
an exercise test evaluating physical capacity and
blood pressure response to exercise, is recommended
(see Central Illustration). This approach is, however,
controversial due to absent/limited data regarding
the prognostic value of pre-pregnancy exercise
testing in the setting of AS (4).
Even women with AS who remain asymptomatic
during pregnancy are subject to additional hemody-
namic stress at the time of delivery and the imme-
diate postpartum period. These women may
therefore become symptomatic at the time of de-
livery and should be managed in a team approach,
including experienced cardiologists, obstetricians,
and anesthesiologists. In asymptomatic patients in
good clinical condition with normal cardiac function,
spontaneous labor is generally preferred to induced
labor (1). By contrast, there is less consensus on the
recommended mode of delivery in symptomatic pa-
tients. Generally, vaginal delivery carries a lower risk
of complications for mother and fetus. Compared
with Cesarean section, it normally causes smaller
shifts in blood volume, less hemorrhage, the absence
of abdominal surgery, decreased thrombogenic risk,
and fewer infections. Furthermore, the hypertrophi-
ed left ventricle in AS may be sensitive to abrupt
changes in pre-load (e.g., from anesthetic agents or
FIGURE 3 Predictors of Small for Gestational Age Infants
0.1 0.2 0.5 1.0 2.0 5.0 10.0 50.020.0
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Severe aortic stenosis
Peak aortic gradient (per 10 mm Hg)





1.081 [95% CI 0.931–1.255]
1.944 [95% CI 0.434–8.706]
1.504 [95% CI 0.336–6.733]
2.917 [95% CI 0.502–16.95]
3.333 [95% CI 0.739–15.04]
7.636 [95% CI 1.431–40.75]
1.358 [95% CI 1.048–1.759]
1.400 [95% CI 0.993–1.971]
1.095 [95% CI 0.121–9.959]
2.000 [95% CI 0.463–8.644]
3.300 [95% CI 0.695–15.67]
4.870 [95% CI 0.571–41.53]
*
*
Forrest plots illustrating the results of the univariate logistic regression analysis for adverse fetal outcome (small for gestational age). Severe
aortic stenosis and peak aortic gradient were predictive of worse fetal outcome. An asterisk denotes significant results. Abbreviations as in
Figure 1.
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hemorrhage). Early epidural analgesia is generally
recommended. Cesarean section should be reserved
mainly for obstetric indications, or in case of
aortic dilation or overt heart failure (1). Nevertheless,
in some centers, Cesarean section seems to be a
preferred mode of delivery in women with AS.
This may be explained by various factors related
to personal physicians’ and mothers’ preferences,
cultural aspects, local standards, and logistical rea-
sons affecting the choice of delivery mode.
CENTRAL ILLUSTRATION Evaluation of Women With Moderate or Severe AS
Orwat, S. et al. J Am Coll Cardiol. 2016;68(16):1727–37.
(A) and (B) Preconception counseling. Only patients with severe AS and symptoms, or asymptomatic patients with reduced LVF, abnormal exercise test, or high BNP
plasma levels should be counseled against pregnancy and AS should be treated. (C) Management of women with severe AS during pregnancy. In case of heart failure
symptoms, patients are first treated medically (primarily diuretic agents, in addition to restricting physical activities). If medical treatment is insufficient, percutaneous
aortic balloon valvuloplasty can be considered to delay surgical valve replacement until the postpartum period. In case of persistent severe heart failure symptoms,
despite valvuloplasty, or when patients are not eligible for valvuloplasty, aortic valve replacement (AVR) should be considered during pregnancy. Asymptomatic
patients with normal LVF are followed without treatment. Strenuous physical activities should be avoided. AS ¼ aortic stenosis; BNP ¼ B-type natriuretic peptide;
LVF ¼ left ventricular function; Vmax ¼ peak velocity of blood flow across the valve.
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Although historic series report maternal mortality
rates ranging from 11% to 20% (6,9,15–17), in more
recent series, cardiac event rates were lower, with
approximately 10% of patients experiencing a cardiac
event, and mortality being rare (15,17,18). However,
some of these studies also included women with mild
AS, diluting the clinically interesting group of pa-
tients with moderate/severe AS. The current multi-
national study of 96 pregnant women followed
between 2007 and 2014, and focusing specifically on
moderate or severe AS, showed no maternal mortal-
ity, thus supporting the notion that maternal
morbidity, rather than mortality, is the main clinical
problem in this setting. Previous studies suggest a
risk of heart failure during pregnancy of approxi-
mately 10% (1,15). Our data are consistent with this
estimate, showing that heart failure occurred in 11.5%
of patients with moderate or severe AS. However, in
patients with pre-existing symptoms, pregnancy was
complicated by heart failure in 26.3%. Arrhythmias
are also a recognized, common complication during
pregnancy in this setting, with a reported incidence of
3% to 25% in previous reports (1). In the current se-
ries, arrhythmias were also reported as a complica-
tion, but with a relatively low rate of around 3%.
Overall, 57% of women included in the current
study delivered by Cesarean section. This rate is
comparable to that in a recent AS study (18), but
higher than the overall Cesarean section rate of 42%
reported in the ROPAC registry (19) and in comparison
to previous AS studies (17,20). This difference may be
related to the current study including a larger pro-
portion of patients with severe AS and a considerable
number on anticoagulation. Although current rec-
ommendations support vaginal delivery with an
assisted second stage of labor in the majority of pa-
tients, Cesarean section continues to be advocated by
some physicians in women with severe AS and in
those requiring anticoagulation (1). Furthermore,
country-specific preferences may account for some of
the differences, as discussed in detail previously (21).
Severe fetal complications were rare in the current
study, but pre-term birth and low birth weight were
observed in one-third of patients with severe AS. In
addition, newborns of women with severe AS were
more likely to have a low Apgar score, to present with
low birth weight, and to be small for gestational age.
The underlying reasons remain speculative, but are
likely multifactorial. Women with severe AS had a
significantly shorter pregnancy duration than those
with moderate AS (35.5  6.4 vs. 38.0  4.4;
p ¼ 0.002), potentially related to the higher rate of
Cesarean section in this setting. In addition, hemo-
dynamic compromise due to AS, resulting in reduced
utero-placental blood flow, is a plausible alternative
explanation for the impaired intrauterine fetal
growth seen in this study and is supported by the
higher prevalence of small for gestational age
(accounting for duration of pregnancy) newborns in
the severe AS cohort (22).
The most important predictor of both, maternal
and fetal adverse events in the current study was the
hemodynamic severity of AS. Patients with severe AS
had an approximately 2.8-fold increased risk of
maternal complications and a 7.6-fold increased risk
of fetal complications compared with women with
only moderate AS. Interestingly, the peak aortic
gradient before pregnancy, as a continuous variable,
emerged as the only independent predictor of com-
plications on multivariable logistic regression anal-
ysis. This finding, although conceivable, is novel,
because previous studies could not confirm a statis-
tical association between baseline severity of AS and
outcome in this setting (15,17).
Two women included in this study underwent an
aortic valve intervention during pregnancy. Both pro-
cedures were successful, and the patients continued
to have uneventful pregnancieswith vaginal deliveries
of healthy babies. This illustrates that in experienced
hands, complications can be managed successfully in
the current era; however, the risks associated with
these procedures (especially of fetal loss) should not be
underestimated (23). Therefore, appropriate pre-
conceptional assessment and counseling are para-
mount to avoid pregnancy complications, and to allow
for elective procedures to be performed before preg-
nancy, especially in symptomatic women with severe
AS. Nevertheless, the low complication rate in
asymptomatic patients, even those with hemody-
namically severe AS, supports a conservative approach
and avoidance of prophylactic surgery in this group,
considering the dilemma of managing pregnancy in
the presence of a prosthetic valve (1).
STUDY LIMITATIONS. Due to the multinational na-
ture of the registry, we included pregnancies in
developed and emerging countries. We accept that
outcomes may be different in the latter setting.
However, the vast majority of patients included (74%)
were from resource-rich countries of the European
Union or from the United States. In addition, obstetric
outcomes were not statistically different between the
European Union/United States and the remaining
countries. On the basis of the hemodynamic inclusion
criteria, we also enrolled 13 patients with a mechan-
ical heart valve. It is well appreciated that mechanical
heart valves are associated with increased morbidity
during pregnancy and worse fetal outcomes (24).
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Under hemodynamic aspects, however, we believe
that physiological changes during pregnancy should
affect prosthetic and native valves similarly. In
addition, in this series, no prosthetic valve-related
complication was observed. Furthermore, comparing
morbidity between patients with severe AS and those
with prosthetic valves revealed higher rates of com-
plications in the former group (17.6% vs. 11.5%; 35.3%
vs. 20.8%; and 51.5% vs. 35.8% for heart failure and
cardiac or all-cause hospitalization, respectively),
supporting the notion that the degree of hemody-
namic compromise, rather than sequelae related to
previous surgery relate to higher rates of complica-
tions during pregnancy.
The definition of maternal death used here differs
from the published WHO definition by considering
mortality during pregnancy and within 7 days of de-
livery, as opposed to a period of within 42 days of
termination of pregnancy recommended by the WHO
(25). In contrast to other cardiovascular disorders,
such as Marfan syndrome, pulmonary hypertension
or cardiomyopathy, mortality beyond 1 week post-
partum nevertheless related directly to effect of the
pregnancy on the disease is, however, unlikely in AS
on the basis of available published reports and our
own experience. Thus, longer observation post-
partum should not have significantly altered the re-
sults. In addition, the causality between pregnancy
and later mortality may be difficult to establish in AS.
The current study did not investigate the problem
of ascending aortopathy, which is associated espe-
cially with bicuspid aortic valve disease. Neverthe-
less, we did not observe pregnancy-associated aortic
dissection in our cohort. Awareness of this potential
complication, and appropriate preconception and
pregnancy assessment of aortic dimensions should be
part of routine care for patients with known bicuspid
aortic valve.
Not all of the patients had a pre-pregnancy echo-
cardiographic assessment. We are aware that gradi-
ents are expected to increase with increasing cardiac
output. Therefore, the classification of AS severity
before pregnancy may have been different in some
patients with borderline measurements and first
presentation during advanced pregnancy (i.e., some
of the patients classified to have severe AS during
pregnancy may have had moderate AS if pre-
pregnancy data had been available).
CONCLUSIONS
The current multinational study, including 96 women
with at least moderate AS managed in the current era
during pregnancy, highlights the ongoing challenge
of pregnancy in this setting. Although, the maternal
mortality rate was zero in this cohort, hospitalizations
for cardiac reasons were frequent, and both pre-term
birth and low birth weight were observed in one-third
of patients with severe AS. The fact that heart failure,
the most frequent maternal complication, occurred
predominantly in patients with severe AS who had at
least mild symptoms, indicating intervention already
before pregnancy, emphasizes the importance of
appropriate pre-conception patient evaluation and
counseling.
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